Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S19-S25 , March 2004

A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure

References 

  1. The advanced glaucoma intervention study (AGIS) . 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429–440
  2. Alm A, Widengard I, Kjellgren D, et al.  Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79:12–16
  3. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485
  4. Asrani S, Zeimer R, Wilensky J, et al.  Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142
  5. Aung T, Chew PT, Yip CC, et al.  A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001;131:636–642
  6. Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 1999;106:997–1004
  7. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996;103:1916–1924
  8. DuBiner H, Cooke D, Dirks M, et al.  Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(Suppl 4):S353–S360
  9. Gandolfi S, Simmons ST, Sturm R, et al.  Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110–121
  10. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110:609–614
  11. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95–104
  12. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47(Suppl 1):S77–S89
  13. Heijl A, Leske MC, Bengtsson B, et al.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279
  14. Higginbotham EJ, Schuman JS, Goldberg I, et al.  One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286–1293
  15. Kass MA, Heuer DK, Higginbotham EJ, et al.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713
  16. Noecker RS, Dirks MS, Choplin NT, et al.  A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63
  17. Nordmann JP, Mertz B, Yannoulis NC, et al.  A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol. 2002;133:1–10
  18. Oliver JE, Hattenhauer MG, Herman D, et al.  Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am J Ophthalmol. 2002;133:764–772
  19. Parrish RK, Palmberg P, Sheu W-P, XLT Study Group . A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688–703
  20. Preferred Practice Pattern: Primary Open-Angle Glaucoma. American Academy of Ophthalmology, 2000, pg 38
  21. Quigley HA, Enger C, Katz J, et al.  Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol. 1994;112:644–649
  22. Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther. 2002;18:287–291
  23. Stewart WC, Kolker AE, Sharpe ED, et al.  Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol. 2000;130:274–279
  24. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther. 2002;19:275–281

☆ This study was sponsored by Allergan Inc. Paula Bernstein, MS, Scott Whitcup, MD, and Amy Batoosingh, BA, are employees of Allergan Inc.

PII: S0039-6257(03)00191-7

doi: 10.1016/j.survophthal.2003.12.016

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S19-S25 , March 2004

Article Tools

* Image Usage & Resolution